

IMPORTANT UPDATE – PLEASE READ

May 7, 2024

RE: COVID-19 CODES AND THE 2024-25 WVA VACCINE ASSESSMENT GRID

Dear Childhood Vaccine Program Participating Provider,

As follow up to a communication that was sent last week regarding the July 1, 2024-June 30, 2025 WVA Vaccine Assessment Grid, there have been questions regarding how COVID-19 vaccine will be managed after July 1, 2024.

It is likely there will be an updated formula of COVID-19 vaccines for the 2024-2025 respiratory illness season. The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meets on May 16, 2024, to determine the COVID-19 vaccine formulation for the fall 2024/winter 2025 season. The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) meets on June 27 and 28, 2024, to review the FDA’s recommendations and decide which COVID-19 vaccines will be part of the Vaccines for Children (VFC) program for the fall 2024/winter 2025 COVID-19 season.

While waiting for the CDC’s ACIP to provide COVID-19 guidance for the fall 2024/winter 2024 season, the CDC has issued interim guidance to the WA Department of Health’s Childhood Vaccine Program (CVP) regarding the use of existing COVID-19 vaccines after July 1, 2024 (see enclosed May 1, 2024, Vaccine Blurbs). As a result, the following COVID-19 portion of the WVA Vaccine Assessment Grid has been edited. Each of the CPT/NDC codes has a “Grid Expiration Date” whereby providers should not bill the COVID-19 vaccine beyond the listed date of service. Please note that there are varying expiration dates per CPT code, and they are subject to further revision.

CPT Code	NDC Code / Packaging	GRID EXPIRATION DATE	Description	Tradename	WVA Assessment Amount Per Dose from 07/01/2023 to 06/30/2024	WVA Assessment Amount Per Dose from 07/01/2024 to 06/30/2025	Percent Change 07/01/2023 to 07/01/2024
91318	59267-4315-02 (10 pack – 3 dose vial)	REMOVE FROM GRID FOR DATES OF SERVICE AFTER 07/31/2024	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	COVID-19 Vaccine (Pfizer)	\$105	\$113.00	7.6%
91319	59267-4331-02 (10 pack – 1 dose vial)	REMOVE FROM GRID FOR DATES OF SERVICE AFTER 08/31/2024	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	COVID-19 Vaccine (Pfizer)			
91320	00069-2377-10 (10 pack – 1 dose syringe)	REMOVE FROM GRID FOR DATES OF SERVICE AFTER 08/31/2024	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	COMIRNATY® (Pfizer)			
91321	80777-0287-92 (10 pack – 1 dose vial)	REMOVE FROM GRID FOR DATES OF SERVICE AFTER 09/30/2024	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	COVID-19 Vaccine (Moderna)			
91322	80777-0102-95 (10 pack – 1 dose vial)	REMOVE FROM GRID FOR DATES OF SERVICE AFTER 09/30/2024	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	Spikevax™ (Moderna)			

The WVA intends to provide further COVID-19 dosage-based assessment (DBA) guidance for the fall 2024/winter 2025 season after the FDA and CDC meetings referenced above take place. Thank you for your patience while we wait to learn more information.

If you have any questions, please contact info@wavaccine.org.

Best regards,



Patrick Miller, MPH
Administrative Director

Cc: Julia Zell, MA, Esq., Executive Director, WVA
Janel Jorgenson, Vaccine Section Manager, WA DOH

WVA Tax ID: 27-2251833
WVA NPI: 1699092718